Crispr gene editing treatment from Intellia succeeds in Phase 3 trial

Crispr gene editing treatment from Intellia succeeds in Phase 3 trial

Intellia Therapeutics, constructing exterior and firm signal, Cambridge, Massachusetts, USA. Spencer Grant | Universal Images Group | Getty Images Intellia Therapeutics stated its Crispr-based treatment for a uncommon swelling situation met its objectives in a late-stage trial, marking a milestone for the sector of gene editing and placing the corporate on monitor to hunt approval…

Read Full News
Procter & Gamble (PG) Q3 2026 earnings

Procter & Gamble (PG) Q3 2026 earnings

Procter & Gamble on Friday reported quarterly earnings and income that topped analysts’ expectations, as quantity for its merchandise grew for the primary time in a yr. Shares of the corporate rose 4% in premarket buying and selling. Here’s what the corporate reported in contrast with what Wall Street was anticipating, based mostly on a…

Read Full News